New York, NY -- (SBWIRE) -- 12/10/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: JA Solar Holdings Co., Ltd. (ADR) (NASDAQ:JASO), Ruby Tuesday, Inc (NYSE:RT), Gilead Sciences, Inc (NASDAQ:GILD), Axa SA (ADR) (OTCMKTS:AXAHY)
JA Solar Holdings Co., Ltd. (ADR) (NASDAQ:JASO) showed a volume of 2.04 million shares by the end of last trade whereas the average volume of the stock remained 2.73 million shares. The stock opened the session at $8.80 but then moved to $8.60. At that price, the stock showed a negative performance of -3.37%. JA Solar Holdings Co., Ltd. (JA Solar) is engaged in the business of designing, developing, manufacturing and selling solar cell and solar module products. The Company is also engaged in the manufacturing and sales of solar cells. Its principal products are monocrystalline and multicrystalline solar cells and it also manufacture a variety of standard and specialty solar modules. JA Solar sells its products under the JA Solar brand name and also produces original equipment for manufacturer (OEM),
Will JASO Get Buyers Even After The Recent Rally? Find Out Here
Ruby Tuesday, Inc (NYSE:RT) opened the session at $6.84 and closed the session at $7.18. The stock showed a positive performance of 5.28% in previous trading session. Traded with volume of 2.72 million shares in the prior session and the average volume of the stock remained 690,093.00 shares. Ruby Tuesday, Inc., including its wholly-owned subsidiaries, owns and operates Ruby Tuesday, Lime Fresh Mexican, GrillMarlin & Ray’s, and Wok Hay casual dining restaurants. The Company also operates Truffles restaurants pursuant to a license agreement and franchises the Ruby Tuesday, Lime Fresh, and Wok Hay concepts in selected domestic and international markets.
For How Long RT will fight for Profitability? Read This Trend Analysis report
Gilead Sciences, Inc (NASDAQ:GILD) opened the session at $76.07 and closed the session at $75.19. The stock showed a positive performance of 1.62% in previous trading session. Traded with volume of 17.25 million shares in the prior session and the average volume of the stock remained 10.32 million shares. The beta of the stock remained 0.63. Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead’s primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases, such as hepatitis B and C and cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Asia Pacific. The Company’s products include Atripla, Truvada, Viread, Complera/Eviplera, Emtriva, Hepsera,
Why Should Investors Buy GILD After The Recent Gain? Just Go Here and Find Out
Axa SA (ADR) (OTCMKTS:AXAHY) the stock decreased -0.20% and finished the session at $25.37. Traded with volume of 54,829.00 shares in the prior session and the average volume of the stock remained 107,780.00 shares. The beta of the stock remained 2.66. Axa SA (AXA) is a France-based holding company engaged in the business of financial protection, insurance and asset management. It operates in three segments: Life & Savings, Property & Casualty Insurance and Asset Management. The Company’s business involves the sale of savings policies, retirement accounts, estate planning services, health insurance, car and home insurance, insurance against property damage and civil liability, among others, for individual and business clients.
Will AXAHY Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)